Trelegy Ellipta is a dry powder oral inhalation agent that contains fluticasone furoate, umeclidinium, and vilanterol.

Trelegy Ellipta is approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD), and for the maintenance treatment of asthma in patients aged 18 years and older. Trelegy Ellipta is not indicated for relief of acute bronchospasm.

Trelegy Ellipta is administered by oral inhalation once daily.

What are the three drugs contained in Trelegy Ellipta?

• Fluticasone furoate is an inhaled corticosteroid (ICS) which works to help to decrease inflammation in the lungs.
• Umeclidinium is a long-acting muscarinic antagonist (anticholinergic) which works by acting as a bronchodilator to open the airways.
• Vilanterol is a long-acting beta₂-adrenergic agonist (LABA) which also works by acting as a bronchodilator to open the airways.

These ingredient drugs are contained alone or in combination in the following products:

• Trelegy Ellipta (fluticasone/umeclidinium/vilanterol)
• Breo Ellipta (fluticasone/vilanterol)
• Anoro Ellipta (umeclidinium/vilanterol)
• Arnuity Ellipta (fluticasone)
• Incruse Ellipta (umeclidinium)